Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel

PHASE4WithdrawnINTERVENTIONAL

Timeline

Start Date

May 7, 2018

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions

Hepatitis A

Interventions

BIOLOGICAL

Havrix®

One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.